Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Aptamer Group.

    Client Virtual Booth

    APTAMER GROUP

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Aptamer Group
    unitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Innovation Way, York, England YO10 5NY
    Telephone
    Telephone
    +44 (0) 19045677
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://aptamergroup.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/the-aptamer-group/
    Twitter
    Twitter
    https://twitter.com/AptamerGroup

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Aptamer Sciences Inc. Files IND Application for Innovative Liver Cancer Treatment AST-201: A Promising Approach to Address Under Medical Needs

    Details:

    AST-201 is an aptamer-drug conjugate designed to target GPC3 protein, which exhibits high expression levels in specific cancer cells. It is being evaluated for the treatment of liver cancer.


    Lead Product(s): AST-201

    Therapeutic Area: Oncology Product Name: AST-201

    Highest Development Status: IND EnablingProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 25, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Aptamer and PinotBio Collaborate on Drug Conjugates for Targeted Drug Delivery

    Details:

    The companies will combine Aptamer’s Optimer technology with PinotBio’s technology using the chemotherapeutic FL-118 compound with specific linker.


    Lead Product(s): FL-118-based Drug Conjugate

    Therapeutic Area: Oncology Product Name: FL-118

    Highest Development Status: DiscoveryProduct Type: Undisclosed

    Partner/Sponsor/Collaborator: PinotBio

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration June 03, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search